438 related articles for article (PubMed ID: 19036965)
61. Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease.
Weber JJ; Kloock SJ; Nagel M; Ortiz-Rios MM; Hofmann J; Riess O; Nguyen HP
Neuropharmacology; 2018 May; 133():94-106. PubMed ID: 29355642
[TBL] [Abstract][Full Text] [Related]
62. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease.
Bizat N; Hermel JM; Boyer F; Jacquard C; Créminon C; Ouary S; Escartin C; Hantraye P; Kajewski S; Brouillet E
J Neurosci; 2003 Jun; 23(12):5020-30. PubMed ID: 12832525
[TBL] [Abstract][Full Text] [Related]
63. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models.
Marco S; Giralt A; Petrovic MM; Pouladi MA; Martínez-Turrillas R; Martínez-Hernández J; Kaltenbach LS; Torres-Peraza J; Graham RK; Watanabe M; Luján R; Nakanishi N; Lipton SA; Lo DC; Hayden MR; Alberch J; Wesseling JF; Pérez-Otaño I
Nat Med; 2013 Aug; 19(8):1030-8. PubMed ID: 23852340
[TBL] [Abstract][Full Text] [Related]
64. Neocortical neurons cultured from mice with expanded CAG repeats in the huntingtin gene: unaltered vulnerability to excitotoxins and other insults.
Snider BJ; Moss JL; Revilla FJ; Lee CS; Wheeler VC; Macdonald ME; Choi DW
Neuroscience; 2003; 120(3):617-25. PubMed ID: 12895502
[TBL] [Abstract][Full Text] [Related]
65. Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice.
Gu X; Richman J; Langfelder P; Wang N; Zhang S; Bañez-Coronel M; Wang HB; Yang L; Ramanathan L; Deng L; Park CS; Choi CR; Cantle JP; Gao F; Gray M; Coppola G; Bates GP; Ranum LPW; Horvath S; Colwell CS; Yang XW
Neuron; 2022 Apr; 110(7):1173-1192.e7. PubMed ID: 35114102
[TBL] [Abstract][Full Text] [Related]
66. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
[TBL] [Abstract][Full Text] [Related]
67. Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.
Creus-Muncunill J; Ehrlich ME
Neurotherapeutics; 2019 Oct; 16(4):957-978. PubMed ID: 31529216
[TBL] [Abstract][Full Text] [Related]
68. Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease.
Wu J; Ryskamp D; Birnbaumer L; Bezprozvanny I
J Huntingtons Dis; 2018; 7(1):35-50. PubMed ID: 29480205
[TBL] [Abstract][Full Text] [Related]
69. Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice.
Kim W; Seo H
Biochem Biophys Res Commun; 2014 Jan; 443(2):706-11. PubMed ID: 24333873
[TBL] [Abstract][Full Text] [Related]
70. Early TNF-Dependent Regulation of Excitatory and Inhibitory Synapses on Striatal Direct Pathway Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease.
Chambon J; Komal P; Lewitus GM; Kemp GM; Valade S; Adaïdi H; Al Bistami N; Stellwagen D
J Neurosci; 2023 Jan; 43(4):672-680. PubMed ID: 36517241
[TBL] [Abstract][Full Text] [Related]
71. FACS-array-based cell purification yields a specific transcriptome of striatal medium spiny neurons in a murine Huntington disease model.
Miyazaki H; Yamanaka T; Oyama F; Kino Y; Kurosawa M; Yamada-Kurosawa M; Yamano R; Shimogori T; Hattori N; Nukina N
J Biol Chem; 2020 Jul; 295(29):9768-9785. PubMed ID: 32499373
[TBL] [Abstract][Full Text] [Related]
72. HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation.
Carroll JB; Deik A; Fossale E; Weston RM; Guide JR; Arjomand J; Kwak S; Clish CB; MacDonald ME
PLoS One; 2015; 10(8):e0134465. PubMed ID: 26295712
[TBL] [Abstract][Full Text] [Related]
73. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation.
Valenza M; Carroll JB; Leoni V; Bertram LN; Björkhem I; Singaraja RR; Di Donato S; Lutjohann D; Hayden MR; Cattaneo E
Hum Mol Genet; 2007 Sep; 16(18):2187-98. PubMed ID: 17613541
[TBL] [Abstract][Full Text] [Related]
74. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
[TBL] [Abstract][Full Text] [Related]
75. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.
Tang TS; Slow E; Lupu V; Stavrovskaya IG; Sugimori M; Llinás R; Kristal BS; Hayden MR; Bezprozvanny I
Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2602-7. PubMed ID: 15695335
[TBL] [Abstract][Full Text] [Related]
76. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.
Pouladi MA; Xie Y; Skotte NH; Ehrnhoefer DE; Graham RK; Kim JE; Bissada N; Yang XW; Paganetti P; Friedlander RM; Leavitt BR; Hayden MR
Hum Mol Genet; 2010 Apr; 19(8):1528-38. PubMed ID: 20097678
[TBL] [Abstract][Full Text] [Related]
77. Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.
Ermak G; Hench KJ; Chang KT; Sachdev S; Davies KJ
J Biol Chem; 2009 May; 284(18):11845-53. PubMed ID: 19270310
[TBL] [Abstract][Full Text] [Related]
78. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
[TBL] [Abstract][Full Text] [Related]
79. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
80. The selective vulnerability of nerve cells in Huntington's disease.
Sieradzan KA; Mann DM
Neuropathol Appl Neurobiol; 2001 Feb; 27(1):1-21. PubMed ID: 11298997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
